Vitamin C in Post-cardiac Arrest

PHASE2CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

February 15, 2024

Study Completion Date

August 29, 2024

Conditions
Cardiac Arrest
Interventions
DRUG

Vitamin C

Vitamine C will be administered intravenously as ascorbic acid (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands).

DRUG

Thiamine

All patients will receive thiamine 200 mg q 12 hourly for 4 days to limit the conversion of vitamin C to oxalate.

DRUG

Placebos

One group receives a placebo.

Trial Locations (1)

1081 HV

VU Medical Center, Amsterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gelderse Vallei Hospital

OTHER

collaborator

Sint Franciscus Gasthuis

OTHER

collaborator

Tergooiziekenhuizen

UNKNOWN

collaborator

Amphia Hospital

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Noordwest Ziekenhuisgroep

OTHER

collaborator

Maasstad Hospital

OTHER

collaborator

OLVG

NETWORK

lead

Amsterdam UMC, location VUmc

OTHER

NCT03509662 - Vitamin C in Post-cardiac Arrest | Biotech Hunter | Biotech Hunter